These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8103874)

  • 1. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction.
    Lancet; 1993 Sep; 342(8874):759-66. PubMed ID: 8103874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Anglo-Scandinavian Study of Early Thrombolysis.
    Wilcox RG; von der Lippe G; Olsson CG; Jensen G; Skene AM; Hampton JR
    Lancet; 1990 May; 335(8699):1175-8. PubMed ID: 1971034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
    Lancet; 1995 Aug; 346(8971):329-36. PubMed ID: 7623530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.
    de Bono DP; Simoons ML; Tijssen J; Arnold AE; Betriu A; Burgersdijk C; López Bescos L; Mueller E; Pfisterer M; Van de Werf F
    Br Heart J; 1992 Feb; 67(2):122-8. PubMed ID: 1540431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators
    N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study.
    Becker RC; Charlesworth A; Wilcox RG; Hampton J; Skene A; Gore JM; Topol EJ
    J Am Coll Cardiol; 1995 Apr; 25(5):1063-8. PubMed ID: 7897117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-hospital thrombolytic therapy with either alteplase or streptokinase. Practical applications, complications and long-term results in 529 patients.
    Grijseels EW; Bouten MJ; Lenderink T; Deckers JW; Hoes AW; Hartman JA; van der Does E; Simoons ML
    Eur Heart J; 1995 Dec; 16(12):1833-8. PubMed ID: 8682015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group.
    Lancet; 1993 Sep; 342(8874):767-72. PubMed ID: 8103875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
    Sarullo FM; Pasquale PD; D'Alfonso G; Amerigo L; Cannizzaro S; Castello A
    Ital Heart J; 2001 Aug; 2(8):605-11. PubMed ID: 11577835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction.
    Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators
    N Engl J Med; 1997 Oct; 337(16):1124-30. PubMed ID: 9340504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of alteplase for myocardial infarction in two community hospitals.
    Krichbaum DW; Grabavoy G; Finley RC; Hamid I
    Am J Hosp Pharm; 1990 Jul; 47(7):1535-40. PubMed ID: 2114788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction.
    InTIME-II Investigators
    Eur Heart J; 2000 Dec; 21(24):2005-13. PubMed ID: 11102251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study.
    Becker RC; Hochman JS; Cannon CP; Spencer FA; Ball SP; Rizzo MJ; Antman EM
    J Am Coll Cardiol; 1999 Feb; 33(2):479-87. PubMed ID: 9973029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
    Hacke W; Kaste M; Fieschi C; Toni D; Lesaffre E; von Kummer R; Boysen G; Bluhmki E; Höxter G; Mahagne MH
    JAMA; 1995 Oct; 274(13):1017-25. PubMed ID: 7563451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group.
    Lancet; 1990 Jul; 336(8707):71-5. PubMed ID: 1975322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
    ; Van De Werf F; Adgey J; Ardissino D; Armstrong PW; Aylward P; Barbash G; Betriu A; Binbrek AS; Califf R; Diaz R; Fanebust R; Fox K; Granger C; Heikkilä J; Husted S; Jansky P; Langer A; Lupi E; Maseri A; Meyer J; Mlczoch J; Mocceti D; Myburgh D; Oto A; Paolasso E; Pehrsson K; Seabra-Gomes R; Soares-Piegas L; Sùgrue D; Tendera M; Topol E; Toutouzas P; Vahanian A; Verheugt F; Wallentin L; White H
    Lancet; 1999 Aug; 354(9180):716-22. PubMed ID: 10475182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SYNTHESIS expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast-track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke.
    Ciccone A; Valvassori L; Nichelatti M;
    Int J Stroke; 2011 Jun; 6(3):259-65. PubMed ID: 21557814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.
    Sinnaeve P; Alexander J; Belmans A; Bogaerts K; Langer A; Diaz R; Ardissino D; Vahanian A; Pehrsson K; Armstrong P; Van de Werf F;
    Am Heart J; 2003 Jul; 146(1):27-32. PubMed ID: 12851604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ventricular arrhythmias during treatment with alteplase (recombinant tissue plasminogen activator) in suspected acute myocardial infarction.
    Wilcox RG; Eastgate J; Harrison E; Skene AM
    Br Heart J; 1991 Jan; 65(1):4-8. PubMed ID: 1899582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.